I-Mab (IMAB)
0.78
-0.01 (-0.99%)
At close: Apr 02, 2025, 3:59 PM
0.75
-3.64%
After-hours: Apr 02, 2025, 07:57 PM EDT
-0.99% (1D)
| Bid | 0.71 |
| Market Cap | 27.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.42 |
| PE Ratio (ttm) | -0.32 |
| Forward PE | -1.56 |
| Analyst | Buy |
| Ask | 0.88 |
| Volume | 130,616 |
| Avg. Volume (20D) | 316,675 |
| Open | 0.77 |
| Previous Close | 0.79 |
| Day's Range | 0.77 - 0.82 |
| 52-Week Range | 0.76 - 2.00 |
| Beta | 1.15 |
About IMAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Pha...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 17, 2020
Employees 220
Stock Exchange NASDAQ
Ticker Symbol IMAB
Website https://www.i-mabbiopharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for IMAB stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 799.40% from the latest price.
Stock Forecasts2 months ago
+11.97%
I-Mab shares are trading higher. The stock may be ...
Unlock content with
Pro Subscription
